Table 3.
Second trimestera antiretroviral (ARV) exposure detected in meconium from 6 infants
| Infant | Maternal Lopinavir (LPV) prescription start |
Maternal LPV prescription end |
Infant gestational age (GA) |
Meconium LPV, ng/g |
|---|---|---|---|---|
| 1 | 147 days before delivery (GA:15 weeks) | 57 days before delivery (GA: 27.9 weeks) | 252 days (36.0 weeks) | 2401 |
| 2 | 142 days before delivery (GA: 18.29 weeks) | 91 days before delivery (GA: 25.6 weeks) | 270 days (38.6 weeks) | 177 |
| 3 | 138 days before delivery (GA: 19.29 weeks) | 92 days before delivery (GA: 25.9 weeks) | 273 days (39.0 weeks) | 29 |
| Maternal TDFb prescription start | Maternal TDF prescription end | Infant GA | Meconium Tenofovir (TFV), ng/g | |
| 4 | 253 days before delivery (GA: 0 weeks) | 65 days before delivery (GA: 26.9 weeks) | 253 days (36.1 weeks) | 135 |
| 5 | 159 days before delivery (GA: 15.29 weeks) | 75 days before delivery (GA: 27.3 weeks) | 266 days (38.0 weeks) | 22 |
| Maternal Efavirenz (EFV) prescription start | Maternal EFV prescription end | Infant GA | Meconium EFV, ng/g | |
| 6 | 90 days before delivery (GA: 25.71 weeks)c | 84 days before delivery (GA: 26.6 weeks) | 270 days (38.6 weeks) | 356 |
a
2nd trimester defined as the gestational period of >15 and ≤28 weeks.
b
TDF: tenofovir disproxil fumarate, a bioavailable prodrug of tenofovir (TFV)
c
Infant 6’s mother was prescribed EFV for 6 days at the end of the 2nd trimester.